Overview

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

Status:
Completed
Trial end date:
2019-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Licogliflozin